Convenience, safety and Satisfaction in the treatment of Prostate Cancers – ALL IN ONE WITH LORELIN DEPOT 11.25MG – ONCE EVERY 3 MONTHS
- Cancer of the prostate is the most common malignancy in elderly men (> 65 years) and the second most common cause of death in this age group. Leuprorelin acetate has been in clinical use in the palliative treatment of prostate cancer for more than 20 years, but advances continue to be made in terms of convenience and flexibility of administration, and in the incorporation of Leuprorelin acetate into novel treatment regimens. [4]
- [4] J. UROL. UROGYNÄKOL. Sonderheft 3/2002
Lorelin Depot Inj. 11.25mg
LHRH ANALOGUE DEPOT INJECTION
ONCE EVERY 3 MONTHS!
A depot preparation of Leuprorelin Acetate with Microencapsulated formulation which
• Demonstrates continuous release of drug.
• Offers effective suppression of Testosterone after a SC or IM injection.
• Offers effective suppression of Testosterone after a SC or IM injection.
Lorelin depot is recommended for
• Prostate Cancer
• Endometriosis
• Uterine Leiomyomata
• Central Precocious Puberty
• Endometriosis
• Uterine Leiomyomata
• Central Precocious Puberty
Leuprorelin is 80 times more potent than natural LHRH.
Sustained occupation of pituitary GnRH receptors by Leuprorelin results in desensitization and/or downregulation of receptors in the anterior pituitary, thereby suppressing gonadotrophin release and reducing testosterone release by the human testes to castrate levels.
It act directly on cell growth in human prostatic cancer cells, behaving like a negative growth factor. [12]
It offers maximum androgen blockade in combination with Nonsteroidal Anti Androgen (NSAA) as compared to NSAA Monotherapy having the highest estimated quality adjusted survival. [13]
Brief Prescribing Information:
Drug Description: Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin –releasing hormone (GnRH or LH-RH). The analog possesses greater potency than the natural hormone. When and How to give: Advanced Prostate Cancer: for effective hormone control – Lorelin 11.25mg once in 3 months along with antiandrogen to control testosterone flares.Endometriosis: for management of endometriosis, including pain relief and reduction of endometriotic lesions. Prescribed with Norethindrone acetate 5mg daily. Helps in preventing recurrence symptoms. Duration of initial treatment or retreatment should be limited to 6 months.Uterine Leiomyomata (Fibroids): Lorelin 11.25mg, 3 monthly concomitantly with iron therapy is indicated for preoperative hematologic improvement of patients with anemia caused by fibroids. Description: Lorelin Depot injection is a fine powder containing 11.25mg of Leuprorelin acetate, a synthetic analogue of LHRH in a vial. Indications: Prostatic Cancer, Endometriosis, Uterine Leiomyomata, Premenopausal Breast Cancer & Central Precocious Puberty. Mode of administration: Given IM/SC. Absorption: Mean plasma concentration 36.3ng/ml at 4 hours. Released at a constant rate following the onset of steady state levels during third week after dosing & these levels decline to near the lower limit of detection by 12 weeks. Distribution: Mean steady state volume of distribution was 27L. In vitro binding to human plasma proteins = 43-49%. Metabolism: One mg bolus of leuprolide acetate IV – mean systemic clearance 7.6l/h. Terminal elimination half-life of approx. 3 hours. Less than 5% of the dose was recovered as parent metabolite in the urine. Precautions: Mutagenesis, Impairment of fertility, Pregnancy Category X, Teratogenic, Nursing mothers, Geriatric use. Side Effects: Hot flushes, Sweating, Amenorrhea, Withdrawal bleeding, Reduced libido, Vaginal dryness, Breast tenderness, Arthralgia, Myalgia, Peripheral edema, Dizziness, Headache, Nausea, Vomiting, Constipation, Injection site reaction, Thrombophlebitis, Decreased bone mass. Storage: Store at room temperature. M.R.P: 21,000/- PKR
Ref: [12] LEUPRORELIN ACETATE IN PROSTATE CANCER: A EUROPEAN UPDATE – J. UROL. UROGYNÄKOL. Sonderheft 3/2002
[13] Guidelines on Prostate Cancer – European Association of Urology 2015 – Pg 60
Best Medical Services
Product Portfolio
Avoid platelet transfusions in successive chemotherapies with Thrombomax!
Thrombocytopenia may compromise cancer treatment, causing chemotherapy dose reductions, schedule alterations, or the need for platelet transfusions.
Read more
Fight Colorectal Cancer differently!
Colorectal cancer is a major cause of morbidity and mortality, being one of the most common malignant tumors in the world.
Read more
Convenience, safety and Satisfaction in the treatment of Prostate Cancers – ALL IN ONE WITH LORELIN DEPOT 11.25MG – ONCE EVERY 3 MONTHS
Cancer of the prostate is the most common malignancy in elderly men
Read more
Accelerate neutrophil recovery with AMGOFIL
Chemotherapy-induced neutropenia is a common and serious complication of myelosuppressive chemotherapy. It is associated with significant morbidity and mortality, and can increase the overall cost of providing cancer therapy.
Read more
Improve Bone Health with Pamidronate
Some types of cancer may cause bone damage leading to high levels of blood calcium and lesions that cause severe bone pain, bone masses & fractures.
Read more